User login
Diagnosing and Managing Tardive Dyskinesia
Earn free CME/CE credit by learning about tardive dyskinesia (TD), a syndrome of involuntary movements associated with the long-term use of antipsychotic medications.
Click here to read the supplement and earn free CME/CE credits by learning about TD and evidence based treatments.
Educational Objectives
- Discuss the diagnosis, differential diagnosis and risk factors for TD
- Identify the prevalence of TD with antipsychotics
- Use the AIMS examination
- Review the evidence and non-evidence based treatments for TD
- Individualize treatment choices, giving consideration to efficacy, safety, long-term data, and unique patient characteristics
- Formulate appropriate treatment regimens considering
the emergence of new FDA approved treatments for TD
Click here to read the supplement.
Earn free CME/CE credit by learning about tardive dyskinesia (TD), a syndrome of involuntary movements associated with the long-term use of antipsychotic medications.
Click here to read the supplement and earn free CME/CE credits by learning about TD and evidence based treatments.
Educational Objectives
- Discuss the diagnosis, differential diagnosis and risk factors for TD
- Identify the prevalence of TD with antipsychotics
- Use the AIMS examination
- Review the evidence and non-evidence based treatments for TD
- Individualize treatment choices, giving consideration to efficacy, safety, long-term data, and unique patient characteristics
- Formulate appropriate treatment regimens considering
the emergence of new FDA approved treatments for TD
Click here to read the supplement.
Earn free CME/CE credit by learning about tardive dyskinesia (TD), a syndrome of involuntary movements associated with the long-term use of antipsychotic medications.
Click here to read the supplement and earn free CME/CE credits by learning about TD and evidence based treatments.
Educational Objectives
- Discuss the diagnosis, differential diagnosis and risk factors for TD
- Identify the prevalence of TD with antipsychotics
- Use the AIMS examination
- Review the evidence and non-evidence based treatments for TD
- Individualize treatment choices, giving consideration to efficacy, safety, long-term data, and unique patient characteristics
- Formulate appropriate treatment regimens considering
the emergence of new FDA approved treatments for TD
Click here to read the supplement.
The Clinical Conundrum in Managing Preterm Birth: Balancing Historical Trial Results, Society Guidelines, and Clinical Experience with a Contradictory Trial Outcome
Since its approval in 2011, 17-alpha hydroxyprogesterone caproate (17-OHPC, trade name Makena®, AMAG Pharmaceuticals, Inc, Waltham, MA) has been designated the “standard of care “ for treating pregnant patients with a history of spontaneous preterm birth (SPTB) by the American College of Obstetricians and Gynecologists (ACOG), the Society for Maternal Fetal Medicine (SMFM), and the American College of Nurse Midwives (ACNM). Several clinical trials and years of clinical experience have demonstrated its safety and efficacy.
This CME supplement details results of the PROLONG (Progestin’s Role in Optimizing Neonatal Gestation) trial evaluating 17-OHPC in patients with a history of a prior spontaneous singleton preterm delivery.
To receive CME credit, please
read the article and go to www.omniaeducation.com/ptb
to access the posttest and evaluation.
Since its approval in 2011, 17-alpha hydroxyprogesterone caproate (17-OHPC, trade name Makena®, AMAG Pharmaceuticals, Inc, Waltham, MA) has been designated the “standard of care “ for treating pregnant patients with a history of spontaneous preterm birth (SPTB) by the American College of Obstetricians and Gynecologists (ACOG), the Society for Maternal Fetal Medicine (SMFM), and the American College of Nurse Midwives (ACNM). Several clinical trials and years of clinical experience have demonstrated its safety and efficacy.
This CME supplement details results of the PROLONG (Progestin’s Role in Optimizing Neonatal Gestation) trial evaluating 17-OHPC in patients with a history of a prior spontaneous singleton preterm delivery.
To receive CME credit, please
read the article and go to www.omniaeducation.com/ptb
to access the posttest and evaluation.
Since its approval in 2011, 17-alpha hydroxyprogesterone caproate (17-OHPC, trade name Makena®, AMAG Pharmaceuticals, Inc, Waltham, MA) has been designated the “standard of care “ for treating pregnant patients with a history of spontaneous preterm birth (SPTB) by the American College of Obstetricians and Gynecologists (ACOG), the Society for Maternal Fetal Medicine (SMFM), and the American College of Nurse Midwives (ACNM). Several clinical trials and years of clinical experience have demonstrated its safety and efficacy.
This CME supplement details results of the PROLONG (Progestin’s Role in Optimizing Neonatal Gestation) trial evaluating 17-OHPC in patients with a history of a prior spontaneous singleton preterm delivery.
To receive CME credit, please
read the article and go to www.omniaeducation.com/ptb
to access the posttest and evaluation.
Hot Topics in Primary Care 2019
Topics include:
- Naproxen vs Opioids
- Cluster Headache
- Reducing Cardiovascular Events in Patients with Type 2 Diabetes Mellitus
This supplement offers the opportunity to earn a total of 1 CME credit.
Credit is awarded for successful completion of the online evaluation at the link below. This link may also be found within the supplement on the first page of the article.
- Reducing Cardiovascular Events in Your Patients with Type 2 Diabetes Mellitus
- To receive CME credit, please read the journal article and, upon completion, go to www.pceconsortium.org/CVEvents to complete the online post-test and receive your certificate of credit.
Topics include:
- Naproxen vs Opioids
- Cluster Headache
- Reducing Cardiovascular Events in Patients with Type 2 Diabetes Mellitus
This supplement offers the opportunity to earn a total of 1 CME credit.
Credit is awarded for successful completion of the online evaluation at the link below. This link may also be found within the supplement on the first page of the article.
- Reducing Cardiovascular Events in Your Patients with Type 2 Diabetes Mellitus
- To receive CME credit, please read the journal article and, upon completion, go to www.pceconsortium.org/CVEvents to complete the online post-test and receive your certificate of credit.
Topics include:
- Naproxen vs Opioids
- Cluster Headache
- Reducing Cardiovascular Events in Patients with Type 2 Diabetes Mellitus
This supplement offers the opportunity to earn a total of 1 CME credit.
Credit is awarded for successful completion of the online evaluation at the link below. This link may also be found within the supplement on the first page of the article.
- Reducing Cardiovascular Events in Your Patients with Type 2 Diabetes Mellitus
- To receive CME credit, please read the journal article and, upon completion, go to www.pceconsortium.org/CVEvents to complete the online post-test and receive your certificate of credit.
Hot Topics in Primary Care 2019
Click here to read Hot Topics in Primary Care.
This supplement includes 4 CME credits (scroll down for more information).
Topics include:
- Chronic Kidney Disease in Type 2 Diabetes
- Heart Failure in Type 2 Diabetes
- Diabetes Management
- Naproxen vs Opioids
- Statin Selection
- Insomnia in Alzheimer's Disease
- Cluster Headache
- Irritable Bowel Syndrome
This supplement offers the opportunity to earn a total of 4 CME credits.
Credit is awarded for scucesful completion of the online evaluations at the links below. These links may also be found within the supplement on the first page of each article.
- Chronic Kidney Disease in Type 2 Diabetes: Optimizing Glucose-Lowering Therapy
- To receive CME credit, please read the journal article and, upon completion, go to www.pceconsortium.org/DKD to complete the online post-test and receive your certificate of credit.
- Diabetes Management Update: Individualizing Treatment
- To receive CME credit, please read the journal article and, upon completion, go to www.pceconsortium.org/DM to complete the online post-test and receive your certificate of credit.
- Identification and Management of Insomnia in Alzheimer's Disease
- To receive CME credit, please read the journal article and, upon completion, go to www.pceconsortium.org/insomnia to complete the online post-test and receive your certificate of credit.
- Patient-Centric Care of Diarrhea-Predominant Irritable Bowel Syndrome
- To receive CME credit, please read the journal article and, upon completion, go to www.pceconsortium.org/IBSD to complete the online post-test and receive your certificate of credit.
Click here to read Hot Topics in Primary Care.
This supplement includes 4 CME credits (scroll down for more information).
Topics include:
- Chronic Kidney Disease in Type 2 Diabetes
- Heart Failure in Type 2 Diabetes
- Diabetes Management
- Naproxen vs Opioids
- Statin Selection
- Insomnia in Alzheimer's Disease
- Cluster Headache
- Irritable Bowel Syndrome
This supplement offers the opportunity to earn a total of 4 CME credits.
Credit is awarded for scucesful completion of the online evaluations at the links below. These links may also be found within the supplement on the first page of each article.
- Chronic Kidney Disease in Type 2 Diabetes: Optimizing Glucose-Lowering Therapy
- To receive CME credit, please read the journal article and, upon completion, go to www.pceconsortium.org/DKD to complete the online post-test and receive your certificate of credit.
- Diabetes Management Update: Individualizing Treatment
- To receive CME credit, please read the journal article and, upon completion, go to www.pceconsortium.org/DM to complete the online post-test and receive your certificate of credit.
- Identification and Management of Insomnia in Alzheimer's Disease
- To receive CME credit, please read the journal article and, upon completion, go to www.pceconsortium.org/insomnia to complete the online post-test and receive your certificate of credit.
- Patient-Centric Care of Diarrhea-Predominant Irritable Bowel Syndrome
- To receive CME credit, please read the journal article and, upon completion, go to www.pceconsortium.org/IBSD to complete the online post-test and receive your certificate of credit.
Click here to read Hot Topics in Primary Care.
This supplement includes 4 CME credits (scroll down for more information).
Topics include:
- Chronic Kidney Disease in Type 2 Diabetes
- Heart Failure in Type 2 Diabetes
- Diabetes Management
- Naproxen vs Opioids
- Statin Selection
- Insomnia in Alzheimer's Disease
- Cluster Headache
- Irritable Bowel Syndrome
This supplement offers the opportunity to earn a total of 4 CME credits.
Credit is awarded for scucesful completion of the online evaluations at the links below. These links may also be found within the supplement on the first page of each article.
- Chronic Kidney Disease in Type 2 Diabetes: Optimizing Glucose-Lowering Therapy
- To receive CME credit, please read the journal article and, upon completion, go to www.pceconsortium.org/DKD to complete the online post-test and receive your certificate of credit.
- Diabetes Management Update: Individualizing Treatment
- To receive CME credit, please read the journal article and, upon completion, go to www.pceconsortium.org/DM to complete the online post-test and receive your certificate of credit.
- Identification and Management of Insomnia in Alzheimer's Disease
- To receive CME credit, please read the journal article and, upon completion, go to www.pceconsortium.org/insomnia to complete the online post-test and receive your certificate of credit.
- Patient-Centric Care of Diarrhea-Predominant Irritable Bowel Syndrome
- To receive CME credit, please read the journal article and, upon completion, go to www.pceconsortium.org/IBSD to complete the online post-test and receive your certificate of credit.
Bipolar Depression: Diagnostic Dilemmas to Innovative Treatments
Bipolar disorder (BD) is a severe, lifelong disorder associated with high rates of nonrecovery, chronicity, and premature mortality. The actionable opportunity for reducing the morbidity and mortality of BD is to address current unmet needs.
Click here to read the supplement and earn 1 AMA Category 1 Credit TM by learning about these unmet needs, and recent advances and novel strategies for management of depression in BD.
Educational Objectives
- Discuss the prevalence of bipolar disorder in different psychiatric patients.
- Describe the different symptoms that occur in children, adolescents, and adults.
- Use the evidence base, including FDA approval for different treatments, to inform therapy for bipolar depression.
- Provide details to ensure that physicians consider the potential metabolic profile of antipsychotics when choosing agents.
Click here to read the supplement.
Bipolar disorder (BD) is a severe, lifelong disorder associated with high rates of nonrecovery, chronicity, and premature mortality. The actionable opportunity for reducing the morbidity and mortality of BD is to address current unmet needs.
Click here to read the supplement and earn 1 AMA Category 1 Credit TM by learning about these unmet needs, and recent advances and novel strategies for management of depression in BD.
Educational Objectives
- Discuss the prevalence of bipolar disorder in different psychiatric patients.
- Describe the different symptoms that occur in children, adolescents, and adults.
- Use the evidence base, including FDA approval for different treatments, to inform therapy for bipolar depression.
- Provide details to ensure that physicians consider the potential metabolic profile of antipsychotics when choosing agents.
Click here to read the supplement.
Bipolar disorder (BD) is a severe, lifelong disorder associated with high rates of nonrecovery, chronicity, and premature mortality. The actionable opportunity for reducing the morbidity and mortality of BD is to address current unmet needs.
Click here to read the supplement and earn 1 AMA Category 1 Credit TM by learning about these unmet needs, and recent advances and novel strategies for management of depression in BD.
Educational Objectives
- Discuss the prevalence of bipolar disorder in different psychiatric patients.
- Describe the different symptoms that occur in children, adolescents, and adults.
- Use the evidence base, including FDA approval for different treatments, to inform therapy for bipolar depression.
- Provide details to ensure that physicians consider the potential metabolic profile of antipsychotics when choosing agents.
Click here to read the supplement.
Diagnosing and Managing Multiple Sclerosis: A Personalized Approach
Multiple sclerosis (MS) is one of the leading causes of disability and many efforts have been implemented to help expediate diagnosis and initiate early, effective treatment. With rapidly changing guidelines and treatment indications, it can be difficult discerning when to start a disease-modifying therapy in the early spectrum of MS, such as clinically and radiologically isolated syndrome; how to discuss MS management in women of childbearing age; or how to use the new guidelines to confirm an MS diagnosis.
Click here to read the supplement and earn 1 AMA Category 1 Credit TM by learning about these topics.
Click here to read the supplement.
Multiple sclerosis (MS) is one of the leading causes of disability and many efforts have been implemented to help expediate diagnosis and initiate early, effective treatment. With rapidly changing guidelines and treatment indications, it can be difficult discerning when to start a disease-modifying therapy in the early spectrum of MS, such as clinically and radiologically isolated syndrome; how to discuss MS management in women of childbearing age; or how to use the new guidelines to confirm an MS diagnosis.
Click here to read the supplement and earn 1 AMA Category 1 Credit TM by learning about these topics.
Click here to read the supplement.
Multiple sclerosis (MS) is one of the leading causes of disability and many efforts have been implemented to help expediate diagnosis and initiate early, effective treatment. With rapidly changing guidelines and treatment indications, it can be difficult discerning when to start a disease-modifying therapy in the early spectrum of MS, such as clinically and radiologically isolated syndrome; how to discuss MS management in women of childbearing age; or how to use the new guidelines to confirm an MS diagnosis.
Click here to read the supplement and earn 1 AMA Category 1 Credit TM by learning about these topics.
Click here to read the supplement.
Major Depressive Disorder: Unmet Needs and Innovative Treatments
Many of the unmet needs in major depressive disorder (MDD) are modifiable, including improving diagnostic accuracy and offering treatments with faster onset of action, treatments with greater overall efficacy, and treatments that can improve patient functioning.
Click here to read the supplement and earn 1 AMA Category 1 CreditTM by learning about these unmet needs, and innovative strageies working to address them.
Topics include:
- Targeting Unmet Needs in the Treatment of Major Depressive Disorder
- Innovative Strategies for Treatments of Major Depressive Disorder: A Brief Review of Recent Developments
EDUCATIONAL OBJECTIVES
- After completing this activity, the participant should be better able to:
- Treat major depression within 2 weeks.
- Use evidence based treatments to achieve remission in major depression.
- Discuss novel targets including glutamate for treating major depression.
- Utilize treatments with innovative mechanisms to treat major depression.
Click here to read the supplement.
Many of the unmet needs in major depressive disorder (MDD) are modifiable, including improving diagnostic accuracy and offering treatments with faster onset of action, treatments with greater overall efficacy, and treatments that can improve patient functioning.
Click here to read the supplement and earn 1 AMA Category 1 CreditTM by learning about these unmet needs, and innovative strageies working to address them.
Topics include:
- Targeting Unmet Needs in the Treatment of Major Depressive Disorder
- Innovative Strategies for Treatments of Major Depressive Disorder: A Brief Review of Recent Developments
EDUCATIONAL OBJECTIVES
- After completing this activity, the participant should be better able to:
- Treat major depression within 2 weeks.
- Use evidence based treatments to achieve remission in major depression.
- Discuss novel targets including glutamate for treating major depression.
- Utilize treatments with innovative mechanisms to treat major depression.
Click here to read the supplement.
Many of the unmet needs in major depressive disorder (MDD) are modifiable, including improving diagnostic accuracy and offering treatments with faster onset of action, treatments with greater overall efficacy, and treatments that can improve patient functioning.
Click here to read the supplement and earn 1 AMA Category 1 CreditTM by learning about these unmet needs, and innovative strageies working to address them.
Topics include:
- Targeting Unmet Needs in the Treatment of Major Depressive Disorder
- Innovative Strategies for Treatments of Major Depressive Disorder: A Brief Review of Recent Developments
EDUCATIONAL OBJECTIVES
- After completing this activity, the participant should be better able to:
- Treat major depression within 2 weeks.
- Use evidence based treatments to achieve remission in major depression.
- Discuss novel targets including glutamate for treating major depression.
- Utilize treatments with innovative mechanisms to treat major depression.
Click here to read the supplement.
Update in Psoriasis: Optimizing Combination Topical Therapies to Improve Adherence and Patient Outcomes
Click here to download this supplement.
A majority of patients with psoriasis are undertreated. In recent years, however, new formulations of topical medications for psoriasis have been introduced, with the goal of enhancing penetration, efficacy, and patient acceptance. Along with new systemic therapies, these treatments allow for more aggressive goals for disease clearance.
Topical medications can be used as monotherapy but combining topical agents can increase efficacy and may allow for use of lower doses with fewer adverse events. Fixed-dose combination treatments combine active ingredients in one vehicle and may improve patient adherence and acceptance by simplifying the treatment regimen.
This supplement provides physicians with education on evidence-based assessment and management of psoriasis, the combination of systemic and topical medications, and strategies for improving patient adherence to treatment regimens.
Click here to download this supplement.
Click here to download this supplement.
A majority of patients with psoriasis are undertreated. In recent years, however, new formulations of topical medications for psoriasis have been introduced, with the goal of enhancing penetration, efficacy, and patient acceptance. Along with new systemic therapies, these treatments allow for more aggressive goals for disease clearance.
Topical medications can be used as monotherapy but combining topical agents can increase efficacy and may allow for use of lower doses with fewer adverse events. Fixed-dose combination treatments combine active ingredients in one vehicle and may improve patient adherence and acceptance by simplifying the treatment regimen.
This supplement provides physicians with education on evidence-based assessment and management of psoriasis, the combination of systemic and topical medications, and strategies for improving patient adherence to treatment regimens.
Click here to download this supplement.
Click here to download this supplement.
A majority of patients with psoriasis are undertreated. In recent years, however, new formulations of topical medications for psoriasis have been introduced, with the goal of enhancing penetration, efficacy, and patient acceptance. Along with new systemic therapies, these treatments allow for more aggressive goals for disease clearance.
Topical medications can be used as monotherapy but combining topical agents can increase efficacy and may allow for use of lower doses with fewer adverse events. Fixed-dose combination treatments combine active ingredients in one vehicle and may improve patient adherence and acceptance by simplifying the treatment regimen.
This supplement provides physicians with education on evidence-based assessment and management of psoriasis, the combination of systemic and topical medications, and strategies for improving patient adherence to treatment regimens.
Click here to download this supplement.
Diagnosing endometriosis: Is laparoscopy the gold standard?
This CME supplement to OBG Management provides readers with an understanding of the following topics:
- The relationship between chronic pelvic pain and endometriosis
- The limitations of laparocopy in the diagnosis of endometriosis
- The emerging role of imaging in the diagnosis of endometriosis
Click Here to read the full supplement and access a posttest and evaluation for CME credit.
This CME supplement to OBG Management provides readers with an understanding of the following topics:
- The relationship between chronic pelvic pain and endometriosis
- The limitations of laparocopy in the diagnosis of endometriosis
- The emerging role of imaging in the diagnosis of endometriosis
Click Here to read the full supplement and access a posttest and evaluation for CME credit.
This CME supplement to OBG Management provides readers with an understanding of the following topics:
- The relationship between chronic pelvic pain and endometriosis
- The limitations of laparocopy in the diagnosis of endometriosis
- The emerging role of imaging in the diagnosis of endometriosis
Click Here to read the full supplement and access a posttest and evaluation for CME credit.